FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1254-1257 April 24, 1997 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by McGuire, W. P. Related Article by Rubin, S. C. PubMed Citation

To the Editor: Rubin and colleagues (Nov. 7 issue)¹ conclude that advanced epithelial ovarian cancers in patients with germ-line BRCA1 mutations have a better prognosis than their sporadic counterparts. Although this may eventually prove to be correct, the methods used in this study raise several questions.

Important prognostic information about the patients with BRCA1 mutations, such as the status of residual disease and the type of chemotherapy used, was said to be unavailable from the patients' charts, although these data are critical in choosing a proper control group. Did the authors attempt to check the original operative reports; to make . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Ben David, Y., Chetrit, A., Hirsh-Yechezkel, G., Friedman, E., Beck, B.D., Beller, U., Ben-Baruch, G., Fishman, A., Levavi, H., Lubin, F., Menczer, J., Piura, B., Struewing, J.P., Modan, B. (2002). Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors. JCO 20: 463-466 [Abstract] [Full Text]  
• Pharoah, P. D. P., Easton, D. F., Stockton, D. L., Gayther, S., Ponder, B. A. J. (1999). Survival in Familial, BRCA1-associated, and BRCA2-associated EpithelialOvarian Cancer. Cancer Res. 59: 868-871 [Abstract] [Full Text]